Key facts
- This page summarizes Invus US Partners LLC's Form 4 filing for LEXICON PHARMACEUTICALS, INC. (LXRX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 09 Aug 2022, 16:48.
Invus US Partners LLC - 05 Aug 2022 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- LXRX
- Reported as of
- 05 Aug 2022
- Net transaction value
- +$368,475
- SEC form
- 4
- Accepted by SEC
- 09 Aug 2022, 16:48:13 UTC
- Prior SEC filing
- 01 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- Invus US Partners LLC, By: /s/ Philip Bafundo , Name: Philip Bafundo, Title: Authorized Person
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Invus US Partners LLC filed Form 4 for LEXICON PHARMACEUTICALS, INC. (LXRX) on 09 Aug 2022.
Change
- Previous filing in this sequence was filed on 01 Aug 2022.
- Current net transaction value: +$368,475.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LXRX
transaction
Common Stock
Purchase
- Transaction value
- $368,475
- Shares
- +147,390
- Change %
- +2.8%
- Price
- $2.50
- Shares after
- 5,451,204
- Date
- 05 Aug 2022
- Ownership
- See Footnotes
- Footnotes
- F1, F2, F4, F5
LXRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 331,545
- Date
- 05 Aug 2022
- Ownership
- Direct
- Footnotes
- F3, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Pursuant to a purchase agreement dated July 27, 2022, between Invus US Partners LLC and the Issuer, on August 5, 2022, Invus US Partners LLC purchased an additional 147,390 shares of common stock, $0.001 par value per share (the "Issuer Common Stock"), following the full exercise by the underwriters of a concurrent public offering of their option to purchase additional shares of Issuer Common Stock.
Footnote F2
These securities are directly held by Invus US Partners LLC
Footnote F3
These securities are directly held by Mr. Raymond Debbane.
Footnote F4
Ulys, L.L.C. is the general partner of Invus US Partners LLC, and Mr. Raymond Debbane is the sole member of Ulys, L.L.C.
Footnote F5
Each of the Reporting Persons (other than to the extent it directly holds securities reported herein) disclaims beneficial ownership of the securities held by the other Reporting Persons, except to the extent of such Reporting Person's pecuniary interest therein, and, pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), each of the Reporting Persons (other than to the extent it directly holds securities reported herein) states that the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 of the Exchange Act or for any other purpose.
SEC remarks
Artal International S.C.A. directly holds 50,859,331 shares of Issuer Common Stock; Invus, L.P. directly holds 35,402,689 shares of Issuer Common Stock; and Invus Public Equities, L.P. directly holds 3,516,214 shares of Issuer Common Stock, which securities are being reported on a separately filed Form 4. For purposes of Section 16 of the Exchange Act, the Reporting Persons may be deemed to be directors by deputization of the Issuer by virtue of Invus, L.P.'s right to designate certain members of the Issuer's board of directors pursuant to a stockholders' agreement between the Issuer and Invus, L.P.